| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Acetylcholine Receptor Blocking Antibody
Test CodeACRBI
CPT Codes
<p>83519</p>
Preferred Specimen
Specimen Type: Serum
Collection Container/Type
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Minimum Volume
0.5 mL
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 14 days
Refrigerated: 14 days
Frozen: 30 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Microbially contaminated • Gross hemolysis • Grossly lipemic
Methodology
Radioimmunoassay (RIA)
Setup Schedule
Set up: Sun, Tues, Thurs; Report available: 4-7 days
Report Available
4-7 days
Limitations
Antibodies may not be found in congenital myasthenia.
Reference Range
<15 % Inhibition
Clinical Significance
Myasthenia Gravis (MG) is an autoimmune neuromuscular disorder characterized by muscle weakness, most commonly due to autoantibody-mediated loss of functional acetylcholine receptors (AChR) in the neuromuscular junction. AChR binding autoantibodies are diagnostic of MG, and are found in 85-90% of MG patients. AChR blocking autoantibodies prevent inter-action of binding antibodies with the AChR. Fewer than 1% of patients have blocking antibodies without binding antibodies. Blocking antibodies are present in about 50% of patients with MG, but rare in other conditions. Therefore, blocking antibodies have utility in ruling out a possible false positive binding assay and detecting the rare patient without AChR binding antibodies.
Performing Laboratory
Quest Diagnostics Nichols Institute-San Juan Capistrano, CA
33608 Ortega Highway
San Juan Capistrano, CA 92675-2042
Last Updated: February 17, 2023